myo-inositol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“We found significant reductions in HOMA-IR (MD −0.6; 95% CI −1.2 to 0.0) and levels of insulin (MD −2.69; 95% CI −5.26 to −0.18) in the intervention group versus control.”
Quoted verbatim from Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.. - Study
- RCT
- Dose
- 2 g myo-inositol twice daily with 200 µg folic acid twice daily, until delivery
- Population
- Multiethnic pregnant women at high risk of gestational diabetes, 12+0 to 15+6 weeks' gestation at recruitment, UK; both arms took 200 µg folic acid twice daily, the control arm in a xylitol placebo powder; HOMA-IR measured at 28 weeks' gestation
Effect -0.6 mean difference, 95% CI -1.2 to 0
Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.2022PMID:35277398Permalink
Keep reading
- Everything the graph holds on myo-inositol
- Every compound studied against HOMA-IR
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45QS4KTZ93EJBYF6NGWQTPC